BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.

专注于开发代谢疾病疗法的生物技术公司BioAge Labs Inc向美国证券交易委员会提交了一份申请，要求在首次公开募股中筹集至多1亿美元。

The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024.

该公司成立于2015年，计划在纳斯达克上市，代号为BIOA。BioAge实验室于2024年5月31日秘密提交了申请。

Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.

高盛、摩根士丹利、杰弗里斯和花旗是这笔交易的联合账簿管理人。没有透露定价条款。

The company’s lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.

该公司的主要药物阿泽拉普拉格是一种口服小分子药物，在八项1期临床试验中，265名患者耐受性良好。

Also Read: Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data.

另请阅读：新上市的肥胖玩家Fractyl Health分享了令人鼓舞的临床前数据。

In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while restoring healthy body composition and improving muscle function.

在临床前肥胖模型中，阿泽拉普拉格能够使胰高血糖素样肽-1受体（GLP-1R）激动剂引起的体重减轻增加一倍以上，同时恢复健康的身体成分并改善肌肉功能。

The company plans to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 trials.

该公司计划在两项2期临床试验中，评估阿泽拉普拉格与GLP-1R激动剂联合使用后在减肥方面取得显著改善的潜力。

The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound by Eli Lilly And Co LLY, with topline results anticipated in the third quarter of 2025.

正在进行的STRIDES临床试验将评估阿泽拉普拉格联合替西帕肽，由礼来公司（EliLilly）和Co-LLY公司（Co-LLY）以Zepbound的名义销售，预计在2025年第三季度取得最终结果。

The second Phase 2 trial will assess azelaprag in combination with semaglutide, marketed as Wegovy by Novo Nordisk A/S NVO, with initiation expected in the first half of 2025.

第二阶段2试验将评估阿泽拉普拉格联合semaglutide，由诺和诺德公司（Novo Nordisk A/S NVO）以Wegovy的名义销售，预计将于2025年上半年启动。

BioAge also intends to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion.

BioAge还打算在2025年上半年启动阿泽拉普拉格单药治疗的胰岛素敏感性概念验证试验，以支持潜在的适应症扩展。

The company is also developing orally available small-molecule brain-penetrant NLRP3 inhibitors for diseases driven by neuroinflammation and anticipates submitting an Investigational New Drug application for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 trial in the first half of 2026..

该公司还正在开发口服小分子脑渗透剂NLRP3抑制剂，用于治疗由神经炎症引起的疾病，并预计在2025年下半年提交NLRP3抑制剂的研究性新药申请，如果获得批准，将在2026年上半年启动1期试验。。

In February, BioAge Labs completed a Series D financing round of $170 million led by Sofinnova Investments.

2月，BioAge实验室完成了由Sofinnova Investments牵头的1.7亿美元的D轮融资。

Read Next:

阅读下一页：

Alibaba’s Taobao and Tmall Launch New Tech Venture, Eyeing Global Market Growth.

阿里巴巴（Alibaba）旗下的淘宝（Taobao）和天猫（Tmall）推出了新的科技企业，着眼于全球市场的增长。

Photo by Vidmir Rais via PixabayMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Vidmir Rais通过PixabayMarket News拍摄的照片和Benzinga API提供给您的数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。